Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linezolid: a new antibiotic.

Y Q Xiong1, M R Yeaman, A S Bayer

  • 1Department of Medicine, Division of Infectious Diseases, Research & Education Institute, St. John's Cardiovascular Research Center, LAC-Harbor UCLA Medical Center, Torrance, California 90059, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Antimicrobial agents and chemotherapy·2017
Same author

Electric field modification of magnetism in Au/La2/3Ba1/3MnO3/Pt device.

Scientific reports·2015
Same author

Electric field manipulation of magnetic and transport properties in SrRuO3/Pb(Mg1/3Nb2/3)O3-PbTiO3 heterostructure.

Scientific reports·2014
Same author

Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2013
Same author

Antimicrobial peptides versus invasive infections.

Current topics in microbiology and immunology·2006
Same author

Low-level resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein 1 in vitro associated with qacA gene carriage is independent of multidrug efflux pump activity.

Antimicrobial agents and chemotherapy·2006
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Linezolid, a novel oxazolidinone antibiotic, is approved for treating resistant bacterial infections. It offers a new mechanism of action, showing efficacy against Gram-positive pathogens.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Linezolid is the first approved oxazolidinone antibiotic, a new structural class in 35 years.
  • It targets Gram-positive bacterial infections, including methicillin-resistant Staphylococcus and vancomycin-resistant Enterococcus.
  • Its approval marks a significant advancement in combating resistant bacterial strains.

Purpose of the Study:

  • To introduce linezolid as a novel therapeutic agent.
  • To describe its unique mechanism of action and spectrum of activity.
  • To present its efficacy in preclinical models and clinical trials.

Main Methods:

  • Review of linezolid's chemical structure and mechanism of action.
  • Assessment of in vitro activity against various Gram-positive bacteria and anaerobes.

Related Experiment Videos

  • Evaluation of efficacy in animal models of infection (otitis media, endocarditis, meningitis).
  • Analysis of clinical trial data for skin/soft tissue infections, pneumonia, and other serious infections.

    • Main Results:

    • Linezolid exhibits broad in vitro activity against resistant Gram-positive organisms.
    • It demonstrated efficacy in experimental models of Gram-positive bacterial infections.
    • Clinical trials showed linezolid to be an effective treatment option, comparable to vancomycin.

    Conclusions:

    • Linezolid represents a significant new option for treating serious Gram-positive bacterial infections, particularly those resistant to other antibiotics.
    • Its distinct mechanism of action suggests a low likelihood of cross-resistance with existing agents.
    • Linezolid is a valuable addition to the antimicrobial armamentarium for challenging infections.